


REMARKS

The Specification is amended to correct minor typographical/clerical errors. Support for this amendment is found in the references cited in the Information Disclosure Statement, which is filed concurrently herewith. For example, the following clerical/typographical errors will be corrected upon entry of the amendment: (1) spelling of "pentascchrides," (2) page range for the Journal of Clinical Investigation article, and (3) issue number for the Mebio article. Specific support for the above-numbered amendments is found as follows: (1) page 508 of reference AU, (2) cover page of reference AW, and (3) page 93 of reference AX; wherein the references letter designators refer to the corresponding letter designation on Form PTO-1449, filed concurrently herewith. Therefore, no new matter will be added upon entry of the amendment.

An action on the merits and allowance of the claims is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

A handwritten signature in dark ink, appearing to read "Daniel R. Evans", is written over a horizontal line.

Daniel R. Evans, Ph.D.  
Registration No. 55,868

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413-2220